During the last session, Mereo Biopharma Group Plc ADR (NASDAQ:MREO)’s traded shares were 0.82 million, with the beta value of the company hitting 0.50. At the end of the trading day, the stock’s price was $2.41, reflecting an intraday loss of -0.41% or -$0.01. The 52-week high for the MREO share is $5.02, that puts it down -108.3 from that peak though still a striking 34.44% gain since the share price plummeted to a 52-week low of $1.58. The company’s market capitalization is $373.91M, and the average trade volume was 1.48 million shares over the past three months.
Mereo Biopharma Group Plc ADR (MREO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.11. MREO has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.01.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO) trade information
Mereo Biopharma Group Plc ADR (MREO) registered a -0.41% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.41% in intraday trading to $2.41, hitting a weekly high. The stock’s 5-day price performance is -9.74%, and it has moved by 26.84% in 30 days. Based on these gigs, the overall price performance for the year is -19.93%.
The consensus price target of analysts on Wall Street is $7.5, which implies an increase of 67.87% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4 and $8 respectively. As a result, MREO is trading at a discount of -231.95% off the target high and -65.98% off the low.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 11.89M as predicted by 7 analyst(s). Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to 4.93M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 34.82%. While earnings are projected to return 26.19% in 2025, the next five years will return 17.79% per annum.
MREO Dividends
Mereo Biopharma Group Plc ADR is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 11.79 million shares, is of ADAGE CAPITAL PARTNERS GP, L.L.C.’s that is approximately 1.6566% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $42.45 million.
Also, the Mutual Funds coming in first place with the largest holdings of Mereo Biopharma Group Plc ADR (MREO) shares are Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund and Tema ETF Trust-Tema GLP-1, Obesity & Cardiometabolic ETF . Data provided on Mar 31, 2025 indicates that Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund owns about 759.1 shares. This amounts to just over 0.48 percent of the company’s overall shares, with a $1.83 million market value. The same data shows that the other fund manager holds slightly less at 267.46, or about 0.17% of the stock, which is worth about $0.64 million.
